The Business Of CNS with Acumen's Jim Doherty, Ph.D.

Business Of Biotech

Player FM - Internet Radio Done Right

42 subscribers

تمت الإضافة منذ قبل five أعوام

المحتوى المقدم من Matt Pillar. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Matt Pillar أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

Exile

1
Episode 10: From Refugee to Radical 44:09

منذ 2 years44:09

التشغيل لاحقا

قوائم

إعجاب

احب

44:09

When a young Eva Kollisch arrives as a refugee in New York in 1940, she finds a community among socialists who share her values and idealism. She soon discovers ‘the cause’ isn’t as idyllic as it seems. Little does she know this is the beginning of a lifelong commitment to activism and her determination to create radical change in ways that include belonging, love and one's full self. In addition to Eva Kollisch’s memoirs Girl in Movement (2000) and The Ground Under My Feet (2014), LBI’s collections include an oral history interview with Eva conducted in 2014 and the papers of Eva’s mother, poet Margarete Kolllisch, which document Eva’s childhood experience on the Kindertransport. Learn more at www.lbi.org/kollisch . Exile is a production of the Leo Baeck Institute , New York | Berlin and Antica Productions . It’s narrated by Mandy Patinkin. Executive Producers include Katrina Onstad, Stuart Coxe, and Bernie Blum. Senior Producer is Debbie Pacheco. Associate Producers are Hailey Choi and Emily Morantz. Research and translation by Isabella Kempf. Sound design and audio mix by Philip Wilson, with help from Cameron McIver. Theme music by Oliver Wickham. Voice acting by Natalia Bushnik. Special thanks to the Kollisch family for the use of Eva’s two memoirs, “Girl in Movement” and “The Ground Under My Feet”, the Sophia Smith Collection at Smith College and their “Voices of Feminism Oral History Project”, and Soundtrack New York.…

منذ عام واحد 47:51

MP3•منزل الحلقة

We love to hear from our listeners. Send us a message.

Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzheimer’s disease, advances in the space, the controversies that have ensued on the heels of recent amlyloid-targeting drug approvals, and where Acumen Pharmaceuticals and its lead candidate, Sabirnetug, fit on the landscape. We also cover the critical and growing role of biomarkers in matching Alzheimer's therapies to specific patients, and assess the growing demand for CNS therapeutics.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

فصول

1. The Business Of CNS with Acumen's Jim Doherty, Ph.D. (00:00:00)

2. Neuroscience and Alzheimer's Therapeutics (00:00:04)

3. Advancements in Alzheimer's Therapeutics (00:14:09)

4. Subcutaneous Formulation for Alzheimer's Therapy (00:28:03)

5. Creating a Strategic Path for Success (00:37:11)

244 حلقات

#Science #MBA #Biology #Business #Matt Pillar #Biopharmaceutical #Bioprocess #Biopharma #Medicine #Therapy #Startup #Venturecapital #Entrepreneur #Pharma #Biotech

Business Of Biotech

The Business Of CNS with Acumen's Jim Doherty, Ph.D.

Business Of Biotech

42 subscribers

published منذ عام واحد

MP3•منزل الحلقة

We love to hear from our listeners. Send us a message.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

فصول

1. The Business Of CNS with Acumen's Jim Doherty, Ph.D. (00:00:00)

2. Neuroscience and Alzheimer's Therapeutics (00:00:04)

3. Advancements in Alzheimer's Therapeutics (00:14:09)

4. Subcutaneous Formulation for Alzheimer's Therapy (00:28:03)

5. Creating a Strategic Path for Success (00:37:11)

244 حلقات

#Science #MBA #Biology #Business #Matt Pillar #Biopharmaceutical #Bioprocess #Biopharma #Medicine #Therapy #Startup #Venturecapital #Entrepreneur #Pharma #Biotech

كل الحلقات

Business Of Biotech

1
BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty 56:27

منذ 3 أيام56:27

56:27

We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates risk while enabling immediate capital access to biotech firms. We learn the differences between royalty financing and equity-based funding, how the model addresses traditional risk in biotech financing, the evolution of XOMA's business model, and much more. The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com . Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
BoB@JPM: Tom Chalberg, Ph.D., Genascence 48:00

منذ 10 أيام48:00

48:00

We love to hear from our listeners. Send us a message. Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy. The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com . Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
BoB@JPM: Ran Zheng, Landmark Bio 37:00

منذ 17 يومًا37:00

37:00

We love to hear from our listeners. Send us a message. Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in San Francisco for a discussion on Landmark's role in addressing the ATMP patient access and cost reduction challenges. Along the way, we cover innovations in distributed manufacturing, non-viral gene delivery, and the importance of collaboration with academia to make these transformative therapies widely available. The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com . Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics 45:07

منذ 24 يومًا45:07

45:07

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. Anastasiou discusses the in-house manufacturing quality advantage, how building that capacity opened the door to important partnering opportunities, the company's preparation for clinical trials and IND submissions, and more. From mastering in-house manufacturing to forging strategic partnerships, Capsida aims to redefine genetic medicine. The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com . Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience 43:00

منذ 4 weeks43:00

43:00

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discusses the balance between promising advances in T-cell therapy and the challenges associated with navigating a biotech from platform development to lead candidate status -- including staffing up for and funding the journey. Don't miss this episode, recorded in-person in San Francisco. The 2025 BoB@JPM series is supported by Aslton & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
The Business Of CNS with Acumen's Jim Doherty, Ph.D. 47:51

منذ 5 weeks47:51

47:51

We love to hear from our listeners. Send us a message. Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzheimer’s disease, advances in the space, the controversies that have ensued on the heels of recent amlyloid-targeting drug approvals, and where Acumen Pharmaceuticals and its lead candidate, Sabirnetug, fit on the landscape. We also cover the critical and growing role of biomarkers in matching Alzheimer's therapies to specific patients, and assess the growing demand for CNS therapeutics. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
High-Throughput Discovery With Bioptic's Andrey Dobry 1:13:36

منذ 6 weeks1:13:36

1:13:36

We love to hear from our listeners. Send us a message. Andrey Doronichev, known to many simply as Dobry, is perhaps best known for taking YouTube mobile. You heard that right. If it weren't for him and the teams he led, YouTube might still be a desktop experience. He went on to lead product strategy at Google before launching the startup Optic in 2022. What's that got to do with biotech, you ask? Well, it's Optic where he feels his greatest contributions are to come, and his sights are set squarely on disrupting the way we discover therapeutic targets. On this episode of the Business of Biotech, Dobry, Life Science Leader Chief Editor Ben Comer, and I explore the intersection of AI and biotech, discuss Bioptic's beginnings and its approach to leveraging advanced screening technologies for drug discovery, and address Bioptic's biggest challenges -- data access and industry skepticism. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D. 1:06:32

منذ 7 weeks1:06:32

1:06:32

We love to hear from our listeners. Send us a message. In close partnership woth Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of Biotech, we team up once again with Advancing RNA's Anna Rose Welch to learn about the venture, dubbed the Johns Hopkins University RNA Innovation Center. Anna Rose and I query Drs. Coller and Kim on how the Center came to be, what it has to offer, and how early-stage RNA explorers can benefit from the resource. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall Tales with Tal) 54:04

منذ 8 weeks54:04

54:04

We love to hear from our listeners. Send us a message. Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medical affairs as CMO at Moderna during the COVID 19 pandemic to learn about his latest venture, an mRNA startup called Exsilio Therapeutics. We cover the foundational aspects of the company's start, from the science it's developing, who's been recruited to the team, and how Exsilio charted its way to an $82 million Series A c o-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D. 1:02:34

منذ 9 weeks1:02:34

1:02:34

We love to hear from our listeners. Send us a message. Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers/Howard Hughes postdoctoral fellowship at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center that was preceded by an Oxford Ph.D. in Molecular Genetics. Since 2015, she's been drawing from her immersion in both the business and science disciplines as President & CEO at Meira GTx. On this episode of the Business of Biotech, Dr. Forbes and I go into deep analysis mode as we examine the risks she's taken in her current role, and how she applies her experiences – both good and bad – with handling other people's money to building a biotech company. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
Biotech Story Time With Tal Zaks, M.D. (Part 1) 55:25

منذ 10 weeks55:25

55:25

We love to hear from our listeners. Send us a message. Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business of Biotech surely will. Tal is now leading a new mRNA-centric startup called Exsilio Therapeutics, which Advancing RNA's Anna Rose Welch and I dig into in part two of our talk with Tal, slated for release in early January. Yep, Story Time With Tal is so good, we doubled up the episodes with him. Tune in for insight from the early days of mRNA that you probably haven't heard before, and stay for a glimpse of its future role in therapeutics at Exsilio with one of the foremost thinkers in the space. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D. 52:50

منذ 11 weeks52:50

52:50

We love to hear from our listeners. Send us a message. This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the company's origin story and its place on the greater techbio landscape with one of the men bearing responsibility for Xaira's launch. Vik Bajaj is Managing Director at Foresite Capital Management (which led Xaira's funding) and Cofounder and CEO at Foresite Labs (which helped incubate it, along with ARCH Venture Partners). He takes us behind the scenes, and shares his worldview on the role of advanced computing technology in drug development. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
Manufacturing Partnership With Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski 1:03:50

منذ 12 weeks1:03:50

1:03:50

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jerry McLaughlin, CEO and President at Life Biosciences returns for a visit, and he brought a friend in John Maslowski, newly-appointed CEO at Forge Biologics. We revisit progress at Life Biosciences, followed by a deep look into the gears that make the company's contract development and manufacturing relationship with Forge Biologics go. From CDMO selection to contracting and execution, the episode is packed with actionable insight into building a foundation for collaborative success in advanced biologic therapy development. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D. 45:26

منذ 13 weeks45:26

45:26

We love to hear from our listeners. Send us a message. Revolo Biotherapeutics President and CEO Woody Bryan, Ph.D. is pushing the boundaries of peptide therapeutic delivery. On this episode of the Business of Biotech, we dig into Dr. Bryan’s transition to the CEO chair at the company and how that coincided with an aggressive strategic decision to alter the course of administration of its peptide candidates in allergic and autoimmune diseases. That decision didn’t come lightly and its execution wasn’t easy, but it was an important one for the future of the business. Tune in as Dr. Bryan tells us why they did it, how they did it, and the foundation that decision laid for the company’s growth. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

Business Of Biotech

1
Biopolitics With Allan Shaw 49:54

منذ 14 weeks49:54

49:54

We love to hear from our listeners. Send us a message. The notion that political influence has no place in biology appears poised for a test it hasn’t studied for. Trump administration nominations, from RFK, Jr. to HHS and Vivek Ramaswamy to the newly-proposed DOGE, are driving a storm of speculation over the implications for biotech and other life sciences industries. Throw in the increased probability of the Biosecure Act seeing the light of legislation day under a republican congress, and there’s no shortage of biopolitical pontificating to be done. How might this all play out, and how should biotech builders be obviating? On this episode of the Business of Biotech, we’re joined for some reflection by none other than Allan Shaw. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter . Get in touch with guest and topic suggestions : matt.pillar@lifescienceconnect.com Find Matt Pillar on LinkedIn : https://www.linkedin.com/in/matthewpillar/…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.